ArticleNature communications2026
Assembly-Line Biosynthesis in Living-Cell Emulsions via Tunable Supramolecular Surface Chemistry.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nature organizes enzymes in micro-compartments to enable efficient biosynthesis, inspiring multienzyme cascades for producing complex molecules. However, practical implementation is often limited by enzyme incompatibility, poor substrate transfer, and inefficient catalyst recycling. Here, we report a living biocatalytic platform that operates as a factory-like assembly line within Pickering emulsions. Tunable supramolecular chemistry is used to graft an oil-derived photocatalyst onto enzyme-overexpressing Escherichia coli (E. coli) cells, generating amphiphilic "suprabacteria" that self-assemble at water-oil interfaces and stabilize emulsions. These interfacial suprabacteria accelerate chemoenzymatic and multienzyme cascades, achieving reaction rates up to 45-fold higher than conventional biphasic systems. The platform supports single-step, sequential, and one-pot cascade reactions, including gram-scale benzoin synthesis. Importantly, the dynamic supramolecular linkage enables on-demand dual recycling: either the living-cell conjugate is reused, or the synthetic catalyst is selectively recovered and reattached to fresh cells. This strategy integrates chemical and biological catalysis in a sustainable, scalable platform for future greener industrial biosynthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.